The impact of anti-angiogenic agents... [J Cancer Res Clin Oncol. 2003] - PubMed

loading

Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. [Expert Rev Anticancer Ther. 2009]
Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
Roukos DH, Tzakos A, Zografos G. Expert Rev Anticancer Ther. 2009 Oct; 9(10):1413-6.
Review The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. [Curr Mol Med. 2003]
Review The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.
Rüegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R. Curr Mol Med. 2003 Dec; 3(8):673-91.
Current overview of angiogenesis inhibitors. [Clin Adv Hematol Oncol. 2004]
Current overview of angiogenesis inhibitors.
Ellis LM. Clin Adv Hematol Oncol. 2004 Aug; 2(8):494-6, 520.
Review Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology. [Eur J Cell Biol. 2006]
Review Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
van Kempen LC, Leenders WP. Eur J Cell Biol. 2006 Feb; 85(2):61-8. Epub 2005 Nov 11.
Anti-angiogenesis: the challenges ahead. [MedGenMed. 2003]
Anti-angiogenesis: the challenges ahead.
Mariani SM. MedGenMed. 2003 Apr 30; 5(2):22. Epub 2003 Apr 30.

Angiogenesis and chronic kidney disease. [Fibrogenesis Tissue Repair. 2010]
Angiogenesis and chronic kidney disease.
Maeshima Y, Makino H. Fibrogenesis Tissue Repair. 2010 Aug 5; 3:13. Epub 2010 Aug 5.
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. [J Oncol. 2010]
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis.
Mosch B, Reissenweber B, Neuber C, Pietzsch J. J Oncol. 2010; 2010:135285. Epub 2010 Mar 10.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

The impact of anti-angiogenic agents on cancer therapy.
The impact of anti-angiogenic agents on cancer therapy.
J Cancer Res Clin Oncol. 2003 Nov ;129(11):607-20. Epub 2003 Sep 16 .

PubMed
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor.
Science. 1992 Feb 21 ;255(5047):989-91.

PubMed
Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosi...
Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis.
Am J Physiol Lung Cell Mol Physiol. 2004 Jan ;286(1):L182-8. Epub 2003 Sep 12 .

PubMed
Scientific comment. Basic science of Dupuytren's disease.
Scientific comment. Basic science of Dupuytren's disease.
Ann Chir Main Memb Super. 1992 ;11(5):355-61.

PubMed
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibros...
Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity.
Toxicol Sci. 2003 Sep ;75(1):169-80. Epub 2003 Jun 27 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed